J Cardiovasc Pharmacol. 2026 Jun 5. doi: 10.1097/FJC.0000000000001841. Online ahead of print.
ABSTRACT
Low-dose aspirin has a well-established role in secondary prevention of cardiovascular disease but use in primary prevention remains uncommon due to limited evidence of benefit and risk of adverse effects such as bleeding. While benefit of aspirin in primary prevention may not outweigh risk in the general population, it may still be appropriate for particular groups in which benefit would be greater. Novel biomarkers for cardiovascular risk can help identify these groups. These include imaging markers such as coronary artery calcium scoring and carotid plaque assessment, and laboratory markers such as lipoprotein(a) and high sensitivity C-reactive protein. Use of these biomarkers for more effective risk stratification can delineate groups of patients with greater potential benefit from aspirin and help guide risk-benefit conversations regarding primary prevention.
PMID:42359632 | DOI:10.1097/FJC.0000000000001841